SAFETY OF MODIFIED-RELEASE ORAL MESALAZINE 4.8 G/DAY (800 MG TABLET) COMPARED WITH 2.4 G/DAY (400 MG TABLET) FOR TREATMENT OF ACTIVE ULCERATIVE COLITIS: COMBINED ANALYSIS FROM THREE RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED TRIALS

首页> 外文期刊>Gut: Journal of the British Society of Gastroenterology >SAFETY OF MODIFIED-RELEASE ORAL MESALAZINE 4.8 G/DAY (800 MG TABLET) COMPARED WITH 2.4 G/DAY (400 MG TABLET) FOR TREATMENT OF ACTIVE ULCERATIVE COLITIS: COMBINED ANALYSIS FROM THREE RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED TRIALS

【24h】

SAFETY OF MODIFIED-RELEASE ORAL MESALAZINE 4.8 G/DAY (800 MG TABLET) COMPARED WITH 2.4 G/DAY (400 MG TABLET) FOR TREATMENT OF ACTIVE ULCERATIVE COLITIS: COMBINED ANALYSIS FROM THREE RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED TRIALS

机译：经改良释放的口服美沙拉嗪4.8克/天（800毫克片剂）与2.4克/天（400毫克片剂）的安全性治疗活性溃疡性结肠炎：三种随机，双盲，主动对照试验的综合分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Gut: Journal of the British Society of Gastroenterology》 |2009年第1期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献

1. SAFETY OF MODIFIED-RELEASE ORAL MESALAZINE 4.8 G/DAY (800 MG TABLET) COMPARED WITH 2.4 G/DAY (400 MG TABLET) FOR TREATMENT OF ACTIVE ULCERATIVE COLITIS: COMBINED ANALYSIS FROM THREE RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED TRIALS [J] . Gut: Journal of the British Society of Gastroenterology . 2009,第Suppla1期

机译：经改良释放的口服美沙拉嗪4.8克/天（800毫克片剂）与2.4克/天（400毫克片剂）的安全性治疗活性溃疡性结肠炎：三种随机，双盲，主动对照试验的综合分析
2. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. [J] . Hanauer SB, Sandborn WJ, Dallaire C, Canadian journal of gastroenterology . 2007,第12期

机译：口服缓释美沙明胺4.8 g /天（800 mg片剂）与2.4 g /天（400 mg片剂）相比，用于治疗轻度至中度活动性溃疡性结肠炎：ASCEND I试验。
3. INCREASED EFFICACY OF MODIFIED-RELEASE MESALAZINE 4.8 G/D (800 MG TABLET) COMPARED TO 2.4 G/D (400 MG TABLET) FOR TREATMENT OF MODERATELY ACTIVE ULCERATIVE COLITIS IN PATIENTS WITH A HISTORY OF MORE DIFFICULT TO TREAT DISEASE [J] . Gut: Journal of the British Society of Gastroenterology . 2009,第Suppla1期

机译：改良释放的美沙嗪治疗4.8 G / D（800 MG片剂）与2.4 G / D（400 MG片剂）相比，治疗中度活跃性溃疡性结肠炎的病史更加复杂
4. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial [O] . Stephen B Hanauer, William J Sandborn, Christian Dallaire, 2007

机译：口服缓释美沙明胺4.8 g /天（800 mg片）与2.4 g /天（400 mg片）相比用于治疗轻度至中度活动性溃疡性结肠炎：ASCEND I试验
5. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial [O] . Hanauer, Stephen B, Sandborn, William J, Dallaire, Christian, 2007

机译：口服缓释美沙明胺4.8 g /天（800 mg片剂）与2.4 g /天（400 mg片剂）相比，用于治疗轻度至中度活动性溃疡性结肠炎：ASCEND I试验

SAFETY OF MODIFIED-RELEASE ORAL MESALAZINE 4.8 G/DAY (800 MG TABLET) COMPARED WITH 2.4 G/DAY (400 MG TABLET) FOR TREATMENT OF ACTIVE ULCERATIVE COLITIS: COMBINED ANALYSIS FROM THREE RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED TRIALS

著录项

相似文献

相关主题

期刊订阅